Health Care Stock Check: Complementary Research on Aduro BioTech, XBiotech, Eagle Pharma, Steadymed and Flex Pharma

NEW YORK, April 23, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom. 

Moments ago, Analysts Review released new research updates concerning several important developing situations including The Aduro BioTech Inc (NASDAQ: ADRO), XBiotech Inc. (NASDAQ: XBIT), Eagle Pharmaceuticals (NASDAQ: EGRX), Steadymed Ltd (NASDAQ: STDY), and Flex Pharma Inc. (NASDAQ: FLKS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ADRO Research Report: ( http://get.analystsreview.com/pdf/?c=Aduro%20BioTech&d=23-Apr-2015&s=ADRO ),

XBIT Research Report: ( http://get.analystsreview.com/pdf/?c=XBiotech&d=23-Apr-2015&s=XBIT ),

EGRX Research Report: ( http://get.analystsreview.com/pdf/?c=Eagle%20Pharmaceuticals&d=23-Apr-2015&s=EGRX ),

STDY Research Report: ( http://get.analystsreview.com/pdf/?c=Steadymed&d=23-Apr-2015&s=STDY ),

FLKS Research Report: ( http://get.analystsreview.com/pdf/?c=Flex%20Pharma&d=23-Apr-2015&s=FLKS ).

============

--

Analyst Update: Results Update, Upcoming Financial Events and Conference Participation

Reviewed by: Rohit Tuli, CFA®  

U.S. stocks edged higher on Wednesday as better than expected earnings and strong existing home sales data bolstered investor sentiment. The NASDAQ advanced 0.42% to finish at 5,035.17, its third straight gain and just 13 points below its record close reached on March 10, 2000. The Dow Jones Industrial Average rose 0.49% or 88.35 points to 18,038.27, and the S&P 500 gained 0.50%, or 9.69 points to close the session at 2107.96. European stocks closed with a mixed note on Wednesday, depressed by increasing concern over Greece's bailout negotiations and disappointing earnings. Germany's DAX and Britain's FTSE 100 index slipped 0.6% and 0.5%, respectively, while France's CAC gained 0.36% on Wednesday. Meanwhile, Asian market continued their good run with The Shanghai Composite and Japan's Nikkei closing at new multi-year highs on Wednesday.

Aduro BioTech stock rose 7% on April 20, 2015 to close at $42.80. The Company debuted on NASDAQ on April 15 and announced the closure of its IPO of 8.05 million shares on April 20. It raised an estimated $124.3 million from the IPO, after deducting the underwriting discount and estimated offering expenses.

On April 17, 2015, XBiotech, a clinical-stage biopharmaceutical company, closed its IPO of four million shares of its common stock at an initial public offering price of $19 per share, Yahoo Finance reported. Total amount of the offering was $76 million, before the underwriting discounts and commissions and other company expenses. WR Hambrecht + Co acted as the sole underwriter for the offering.

On April 14, 2015, Eagle Pharmaceuticals and Teva Pharmaceutical Industries Ltd announced that the New Drug Application (NDA) for a liquid Bendamustine Hydrochloride (HCl) rapid infusion product has been accepted for filing by the U.S. Food and Drug Administration (FDA). This NDA requests FDA approval of the rapid infusion Bendamustine HCl product for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

On March 25, 2015, SteadyMed Ltd. closed its IPO of 4.7 million ordinary shares at a price to the public of $8.50 per share, resulting in gross proceeds of approximately $40 million before underwriting discounts and commissions. All of the ordinary shares were offered by SteadyMed, which had begun trading on NASDAQ on March 20, 2015.

On April 21, 2015, Flex Pharma, Inc. announced that Flex Pharma Scientific Co-Founder, Dr. Bruce Bean, presented the Company's data under the abstract he co-authored titled, "Orally-administered TRPV1 and TRPA1 activators inhibit electrically-induced muscle cramps in normal healthy volunteers," during an oral platform presentation at the American Academy of Neurology (AAN) 67th Annual Meeting being held in Washington, D.C.  

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review